A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events

NCT07729475 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Elevated Lipoprotein(a)

Interventions

DRUG: SAL0137 Dose 1
DRUG: SAL0137 Dose 2
DRUG: SAL0137 Dose 3
DRUG: Placebo

Sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd.